ArticleProbiotics and antimicrobial proteins2026
Antimicrobial and Anti-inflammatory Activities of Bacteriocin-like Inhibitory Substance-producing Lactiplantibacillus plantarum against Vaginitis-associated Pathogens.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Vaginal dysbiosis is characterized by disruption of the vaginal microbial community, pathogen overgrowth, and mucosal inflammation. Here, we integrated in vitro screening, whole-genome sequencing, LC-MS/MS profiling, machine learning, and a murine bacterial vaginosis (BV) model to characterize potentially beneficial Lactiplantibacillus plantarum strains. Among 88 Lactobacillaceae isolates, 53 exhibited bacteriocin-like inhibitory substance activity, and 7 demonstrated broad antimicrobial effects against Gardnerella vaginalis, Neisseria gonorrhoeae, Streptococcus agalactiae, and Candida spp. Two L. plantarum strains, CYLB2146 and CYLB2189, were selected based on their antimicrobial activity, adhesion capacity (15.0% and 13.5%, respectively), and significant anti-inflammatory effects, including reductions in IL-6, IL-8, and TNF-α levels (p < 0.05). Genomic analysis revealed plantaricin biosynthetic gene clusters and secondary metabolite pathways, while LC-MS/MS identified predominantly low-molecular-weight and cyclic peptides. Machine-learning models achieved ROC-AUC > 0.92 and prioritized candidate peptides. Cyclo(Tyr-Pro) inhibited multiple pathogens and reduced biofilm formation at sub-inhibitory concentrations without membrane disruption, supporting a potential anti-virulence role. In a murine BV model, probiotic treatment markedly reduced G. vaginalis compared with PBS and MRS controls (51.2 and 41.6-fold). After 5 days, levels decreased to 3.2 and 11.1-fold in live CYLB2146 and CYLB2189 groups and to 3.2 and 0.7-fold in CFS groups, with further reductions by day 10, while controls remained high (34.0 and 50.6-fold). Probiotic treatment also attenuated infection-associated inflammation, particularly TNF-α, and improved vaginal tissue morphology and histological scores. Collectively, CYLB2146 and CYLB2189 exhibited complementary antimicrobial, antibiofilm, and anti-inflammatory activities, supporting their potential as probiotic candidates for BV management.
Indexed as
Identifiers
42911376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.